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Abstract
Cardiogenic shock has an unacceptably high mortality rate and additional tools are needed to improve outcomes. The
Society of Cardiovascular Angiography and Interventions (SCAI) shock severity classification has provided a unified definition
of shock severity that has proven to be reproducible and predictive of survival. However, cardiogenic shock assessment goes
beyond standardizing its severity, and a uniform and practical approach to comprehensive assessment that may guide therapy
in a dynamic state is currently lacking.
Since cardiogenic shock is a rapidly evolving pathophysiological catastrophe, we propose a new assessment tool – the
Houston SHOCK Score – which incorporates dynamic changes. The acronym SHOCK can be used to emphasize five key
aspects of patients in cardiogenic shock: Severity, Hemodynamics, Onset, Causes, and Kinetics. We believe this tool provides
physicians with vital information that will facilitate appropriate care by incorporating dynamic changes in the patient’s profile.
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Background
Cardiogenic shock (CS) is a devastating clinical condition
with an overall mortality rate ranging from 25-50%.1-4
Mortality remains high despite advances in medical
management,2 the adoption of early revascularization and
emergent reperfusion strategies after acute myocardial
infarction (AMI),1 and the advent and widespread utilization
of percutaneous mechanical circulatory support (pMCS)
device therapy.5 In fact, in an analysis of 56,497 patients in the
CATH-PCI registry, the mortality rates from AMI-CS rose
from 27.6% in 2005-2006 to 30.6% in 2011-2013 (P < .0001).5
In addition, the burden on healthcare systems is significant.

CS has an unacceptably high 30-day readmission rate of
18.6% amongst survivors of AMI-CS.6
The Society for Cardiovascular Angiography and
Interventions (SCAI) expert consensus statement on the
classification of CS offers a standardized taxonomy for
providers.7 It supports the early identification and triage of
patients presenting with CS in a simple, readily applicable,
and intuitive manner. The classification is a step closer to the
standardization of a CS definition. Based on this new severity
classification, CS is classified into five categories, from at-risk
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Table 1. Profiles of shock based on invasive hemodynamic assessment.

Abbreviations: CI, cardiac index; PAPi, pulmonary artery pulse pressure index; PCWP, pulmonary capillary wedge
pressure; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; SVRI, systemic vascular resistance
index

(stage A) to extreme CS (Stage E); however, CS assessment
goes beyond standardizing its severity. A comprehensive,
uniform approach is currently lacking, especially one that
considers changes in patients’ clinical or hemodynamic status,
response to therapy, and trajectory. Comprehensive
classification of CS is difficult due to a myriad of reasons that
we will review below.

Classification Complications
First, patients with CS present with a wide spectrum of
presentations. The inability to accurately recognize the
different hemodynamic phenotypes of CS (Table 1) in a
timely fashion is a major contributing factor to poor outcomes.
The current definitions of CS used in clinical trials7-9 require
a systolic blood pressure (SBP) of less than 90 mmHg despite
pressor support with evidence of end-organ hypoperfusion
and/or hemodynamic parameters of reduced cardiac index
(CI). However, septic and hypovolemic shock also manifest
with hypotension and end-organ hypoperfusion (Table 2), and
assessment of hemodynamics is oftentimes not readily
available. Furthermore, mixed forms of shock frequently exist
simultaneously.9 In addition to including absolute blood
pressure parameters in the definition of CS, the degree of
hypotension relative to the patient’s preexisting blood
pressure should be considered in any attempt to redefine the
spectrum of CS. In fact, 5.2% of patients in the SHOCK trial
registry were in CS but had an SBP > 90 mmHg, and 7.1%

E2022112

had no evidence of organ hypoperfusion with an SBP < 90
mmHg; yet, both groups of patients have increased mortality.8
Second, the onset of CS and its impact on outcomes has not
been fully studied. Traditionally, acute onset refers to CS
cases that develop within less than 24 hours of the onset of
symptoms and are typically seen in acute ischemic events or
electrical storms. A subacute onset, defined as symptom onset
of fewer than 7 days, is seen most often in mechanical
complications of myocardial infarction and acute myocarditis.
Finally, chronic onset is defined as symptom onset of greater
than 7 days but is typically seen in patients with known stage
D heart failure.
Third, CS is the final culmination of multiple disease
states. The heterogeneity of CS is akin to heart failure with
preserved ejection fraction (HFpEF) heterogeneity in clinical
trials. An impact on long-term mortality has not been seen in
most HFpEF clinical trials due to the different underlying
pathophysiological mechanisms of diseases that lead to
HFpEF. Outcomes of post-cardiotomy shock vary
dramatically from those of acute myocarditis. A patient
suffering AMI-related CS behaves differently than a stage D
heart failure patient presenting with CS. The hemodynamic
profiles of these two subsets of patient populations are
different, with the latter having higher filling pressures,
pulmonary artery pressures, and a different metabolic

2

JoSH 1(1)

Jumean, et al.

Table 2. Parameters of end-organ hypoperfusion.

Abbreviations: AST/ALT, aspartate aminotransferase/alanine aminotransferase; BP, blood pressure; UOP, urinary output

profile.10 As such, one would expect the hemodynamic goals
of management to differ based on the inciting event.
Lastly, there are aspects of CS that are not addressed in the
current literature, especially responses to initial therapy. Many
questions arise when considering the approach to CS
management. For example, it is not clear if full pMCS support
followed by de-escalation in CS would be superior to a
strategy of tailored escalation of pMCS support, or whether an
approach of maximum pMCS support be utilized routinely in
stages C to E of CS. It is unclear if dynamic changes in the
patient’s hemodynamic status and response to therapy play a
role and whether the “kinetics” of either approach has an
impact on mortality.
Mortality in CS is not solely related to the initial
myocardial insult and the acute drop in CI. In fact, in a metaanalysis of randomized controlled trials of pMCS, Thiele et.
al demonstrated the improvement in hemodynamic profiles of
patients who were supported with pMCS when compared to
those supported with an intra-aortic balloon pump (IABP).11
Reductions in pulmonary capillary wedge pressure and
improvements in CI and mean arterial pressure were observed;
however, an improvement in 30-day mortality was not
found.11 Thus, it remains to be seen if this lack of effect on
mortality was due to the limited power of the study or the true
absence of an effect. Indeed, the complex pathophysiological
way in which the body responds to the initial insult that leads
to progressive cardiac dysfunction varies from one patient to
another. The variations in the activation of systemic
inflammatory response syndrome (SIRS), the extent of
metabolic derangements, the impact of pMCS on SIRS
activation, and the complex interplay between the different
pMCS types and the CS patient (eg, the balance between the
salubrious hemodynamic effects and the complications
associated with these large bore devices) need to be further
studied as they play a major role in the outcomes of these
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patients. As such, the differentiation of CS patients based on
the use of a pMCS device is inadequate. pMCS support should
be tailored to different hemodynamics of shock presentation
and active changes in the patient’s profile. A CS patient who
stabilizes on an IABP may need to be classified differently
than a patient who requires veno-arterial extracorporeal
membrane oxygenation for hemodynamic support due to
refractory CS. Treatment during or following stabilization
should be tailored to the inciting cause of CS and the
likelihood of reversibility of its cause.

Recommendation
Given that CS outcomes are highly dependent on the
severity at the time of presentation AND the above-mentioned
elements including the dynamic changes in the patient’s
profile, which we refer to as “Kinetics,” we propose
incorporating the following five elements to provide a more
comprehensive assessment of the CS patient. The five
variables, encapsulated by the acronym SHOCK are: (1) the
Severity of CS; (2) the Hemodynamic profile of the patient,
(3) the Onset of CS symptoms, (4) the Cause of CS, and (5)
the Kinetics of CS (Figure 1). This approach offers healthcare
providers and researchers a uniform language, a standard
platform, and clinically relevant parameters that include
dynamic changes and response to therapy that allow for a more
accurate portrayal of the clinical picture of a CS patient. This
proposed assessment will support the accurate identification
of CS patients with similar pathophysiology and severity
while addressing most of the aforementioned shortcomings of
the current CS definitions. We believe that this comprehensive
assessment will fulfill a vital need to be able to compare the
effects of different therapies and aid the design of meaningful
trials in specific subsets of patients with CS taking into
consideration the hemodynamic profiles of patients, the
kinetics of patients, and the likelihood of reversibility of
causes.
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The following is a description of the five parameters of the
SHOCK Scoring System.

Table 3. Houston Shock Score.
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classification of shock after invasive and non-invasive
hemodynamic assessments are attained. Patients would be
delineated by one of the following types of shock:
cardiogenic, hypovolemic, distributive, obstructive, or right
ventricular (Table 1). The Houston SHOCK Score assigns a
value of 0 to patients classified as classic; those individuals
classified as mixed or euvolemic are assigned a value of 1.

Onset

Severity
As stated earlier, the SCAI expert consensus statement on
the classification of CS simplifies the severity into one of five
stages, mirroring the Interagency Registry for Mechanically
Assisted Circulatory Support profiling of advanced heart
failure patients.7 In a recent single-center retrospective study
of 10,004 patients admitted to an intensive care unit, the
unadjusted hospital mortality rose steadily as the severity of
CS increased.12 Mortality in stage A was 3.0%, stage B 7.1%,
stage C 12.4%, stage D 40.4%, and stage E 67% (P < .001);
each higher SCAI shock stage was associated with increased
hospital mortality with an adjusted odds ratio of 1.53 to 6.8
(all P < .001).12 Thus, we suggest the first assessment should
include ascertaining the severity of CS via the SCAI system.
The Houston SHOCK Score assigns a value of 0 to patients
classified as stages A-C, and those individuals classified as
stages D or E are assigned a value of 1 (Table 3).

Hemodynamics
While the classic form of CS is frequently seen, the
hemodynamic profile is varied and can be classified in one of
three main presentations:9
1. The classic cold and wet, the most frequently
encountered form, is often seen in AMI-CS
2. Mixed CS (warm and wet), and
3. Euvolemic CS (cold and dry) — often seen in chronic
heart failure patients who present in a decompensated state
Since CS management is dependent on the predominant
phenotype, the second step in our assessment model is to
account for such variability in presentation. The SHOCK
Score encourages users to provide a more detailed
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As mentioned earlier, an AMI-CS patient behaves
differently than a stage D heart failure patient presenting with
CS. Such differentiation is critical when looking at therapeutic
modalities and mortality outcomes. CS onset after AMI
occurred within 24 hours in 74% of patients in the SHOCK
trial registry.13 However, patients in stage D heart failure often
have acute episodes of decompensation. Further, the
hemodynamic profiles of these two subsets of patients are
different with the latter having higher filling pressures,
pulmonary artery pressures, and a different metabolic
profile.10 The Houston SHOCK Score assigns a value of 0 to
patients with acute onset, and those classified as chronic are
assigned a value of 1.

Cause
The only form of CS to have a proven therapy that can
impact mortality is AMI-CS. One may argue that the diagnosis
of AMI-CS is more readily available and, as such, tailored
therapies have existed for decades. Discerning the etiology of
CS upon presentation, however, is difficult, and trying to
ascertain a diagnosis as quickly as possible can pave the wave
to initiating early therapies that can potentially impact
mortality. A broad assessment of CS must be made based on
the cause. We propose the following etiologies: ischemic due
to AMI, ischemic due to a mechanical complication, nonischemic (such as acute myocarditis, acute on chronic stage D
heart failure), right ventricular failure, and electrical storms.
The Houston SHOCK Score assigns a value of 0 to patients
classified as acute reversible and treatable; all other causes are
assigned a value of 1.

Kinetics
Perhaps the least understood aspect of CS management is
the kinetics (dynamic changes in the patient’s profile) and
predicting the outcome of support on pMCS devices. While
some consider pMCS support devices a therapeutic option in
the armamentarium utilized in CS management, it is crucial to
emphasize that in most instances adequate pMCS support is
intended to stabilize (not to treat) a worsening CS patient. In
addition, pMCS devices help determine response to therapy
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Figure 1. The Houston SHOCK Score incorporates the dynamic changes seen in this rapidly evolving hemodynamic
catastrophe. The acronym SHOCK emphasizes five key aspects of patients in cardiogenic shock - Severity, Hemodynamics,
Onset, Causes, and Kinetics - and allows healthcare workers to capture and score the dynamic changes encountered in
cardiogenic shock.

Abbreviations: CI, cardiac index; PCWP, pulmonary capillary wedge pressure; SVRI, systemic vascular resistance index

and improve the overall clinical status and the patient’s
trajectory. While the optimal approach is not fully known, the
ability to stabilize a patient by pMCS support represents a
different group of patients than those that are unable to be
stabilized. By describing the kinetics of CS, i.e. dynamic
changes and responsiveness to therapy, patients can be
classified as stabilized CS vs. refractory shock despite
support. Assessment of the response to therapy is based on
improvement in parameters of perfusion listed in Table 2. This
will allow for quicker triage of worsening patients to dedicated
shock centers. The Houston SHOCK Score assigns a value of
0 to patients classified as stabilized; those individuals
classified as worsening/refractory are assigned a value of 2.

Applicability in Clinical Practice
In addition to offering a standardized approach to
comprehensively assess patients in shock, we believe the
SHOCK Score can serve important purposes that are yet to be
validated. We believe dichotomizing each of the five variables
of the Houston SHOCK Score into a score (Table 3) is
practical. Healthcare providers can quickly triage the “sicker
and refractory” patients to dedicated shock centers and offer
time-sensitive therapies. In addition, admission score can be
validated prospectively for outcomes including mortality. We
believe the higher the score, the higher the acuity of the patient
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resulting in worse inpatient and long-term outcomes. Our
initial scores are arbitrarily dichotomized to 0 and 1 (except
for kinetics where 0 and 2 are used, as those in refractory CS
should be given a higher weighted score in our opinion);
however, we believe that ongoing validation research can
offer a more accurate weighted score for some variables.
Lastly, similar to SCAI Severity Classification of shock, this
scoring system is dynamic and can be applied and utilized in
a dynamic manner incorporating new data and response to
therapy as available. As the kinetic response is a key
component of this score, we believe capturing the score on
admission (for triage purposes), and at 72 hours of admission
may serve to be of prognostic significance that further
validation is necessary. Retrospective data analysis is
currently underway at our institution to validate this score.

Clinical Examples
A 68-year-old male presented with two hours of chest pain
and was found to have large anterior STEMI, for which he
underwent percutaneous coronary intervention (PCI) of the
proximal left anterior descending coronary artery. The left
circumflex and right coronary arteries were chronically
occluded. His blood pressure was 75/44 mmHg on arrival for
which an IABP was placed following the PCI. In the ensuing
hours, the patient had a low blood pressure of 80/50 mmHg,
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cool extremities, S3 gallop, reduced urine output, and elevated
lactic acid requiring the addition of high doses of epinephrine
and norepinephrine. This patient receives a Houston Shock
Score of 4 (S1H0O1C0K2). Such a high score would allow for
a more urgent referral to a shock center and the allocation of
the shock center’s resources to be ready for support escalation
at the time of arrival, such as a percutaneous MCS device
implantation.
A 23-year-old female with familial cardiomyopathy on
milrinone therapy and known reduced left ventricular systolic
function presented for the fourth time in 3 months with 1 week
of 4 pillow orthopnea and dyspnea on minimal exertion. On
presentation, the patient had an SBP of 88 mmHg, S3 gallop
on examination with 3+ pedal edema, and ascites. She
underwent a right heart catheterization that revealed a right
atrial pressure of 19 mmHg, pulmonary artery pressure of
49/35 mmHg, pulmonary capillary wedge pressure (PCWP) of
32 mmHg, and a CI of 1.7 L/m/m2. An Impella 5.5 was placed,
and her repeat hemodynamics at 24 hours showed a right atrial
pressure of 10 mmHg, PCWP of 19 mmHg, and CI of 2.2
L/m/m2. This patient receives a Houston Shock Score of 2
(S0H0O1C1K0). While both patients are classified as “classic”
CS per SCAI definition, the first patient has a higher Houston
Shock Score as he needs more urgent attention, triage to a
shock center, and escalation of therapy.

Conclusion
In summary, CS is a disease state with a heterogeneous
pathophysiology, and its management starts with a
comprehensive assessment that incorporates not only its
severity, but also its hemodynamic profile, onset, cause, and
kinetic response to therapy. The SHOCK Score offers a more
comprehensive and standardized taxonomy that can help
move this field forward.
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